Stem Cell TherapyChronic DiseasesRheumatologyInflammationNeurologyImmunologyBiopharmaBiotechnologyHealth Care
Description
Dianthus Therapeutics, Inc. (Dianthus), a clinical-stage biotechnology company, develops therapies for patients living with severe autoimmune diseases.
The company's lead clinical-stage candidate, claseprubart, is a monoclonal antibody purposefully…
Analysis
Middle-of-the-road
Dianthus Therapeutics, Inc. sits in the middle of our grid: average quality, average price, no obvious signal in either direction. Worth noting: the cash the business generates has lagged behind what the income statement shows.
Valuation data is not available for this company.
Growth is moderate; the safety picture is stretched. The company scores 4/20 on our value-creation score: not creating value.
Flags to be aware of: Reported profits have run ahead of actual cash for several periods. As always: this describes the company's numbers; it is not a recommendation.
360° rank · history
1007550250
Mar 202688
83
2026
All-time high
88
Mar 2026
All-time low
83
Jun 2026
Average rank
86
across all years
Detailed & Historical Ranks
Deep dive into 15 detailed ranks and 3 years of history.
Current202520242023
Price/Sales
1
—
—
—
Price/Earnings
90
—
—
—
Price/Book
44
—
—
—
Dividend Yield
1
—
—
—
Value (overall)
30
—
—
—
Cells are coloured by rank band (red weak → green strong). Sentiment & 360° history begins 2023.